Nkanga Christian

Dr. Nkanga Christian

University of Kinshasa

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Heliyon
Verified
Journal Article
Open access
EKEspoir Kambale Kavungere
Espoir Kambale Kavungere
NCNkanga Christian
Nkanga Christian
BMBlaise-Pascal I. Mutonkole
Blaise-Pascal I. Mutonkole
Alain BapolisiAlain Bapolisi
Alain Bapolisi
DTDaniel O. Tassa
Daniel O. Tassa
PMPatrick B. Memvanga
Patrick B. Memvanga
In the present study, silver nanoparticles (AgNPs) were synthesized using aqueous leaf extracts of three Congolese plant species, namely Brillantaisia patula (BR-PA), Crossopteryx febrifuga (CR-FE) and Senna siamea (SE-SI). The obtained AgNPs were studied for their optical, structural, surface morphological and antibacterial properties. The prepared AgNPs were characterized by using UV-Visible spectra, Transmission Electron Microscopy (TEM), Fourier Transform Infrared Spectroscopy (FTIR), X-ray spectroscopy (EDX) and X-ray diffractometer (XRD). The synthesized nanoparticles were spherical shaped and well-dispersed with average sizes ranging from 45 to 110 nm. The AgNPs derived from BR-PA, CR-FE and SE-SI exhibited higher antibacterial activity against three bacterial pathogens of the human skin compared to their respective crude extracts and AgNO3. This indicated that the biomolecules covering the nanoparticles may enhance the biological activity of metal nanoparticles. Hence, our results support that biogenic synthesis of AgNPs from Congolese plants constitutes a potential area of interest for the therapeutic management of microbial diseases such as infectious skin diseases.

22 August 2020 in Nanomaterials
Verified
Journal Article
Open access
PDF file
Bwalya Angel WitikaBwalya Angel Witika
Bwalya Angel Witika
PMPedzisai Makoni
Pedzisai Makoni
SMScott Kaba Matafwali
Scott Kaba Matafwali
BCBilly Chabalenge
Billy Chabalenge
CMChiluba Mwila
Chiluba Mwila
RWRoderick Bryan Walker
Roderick Bryan Walker
Nanoencapsulation is an approach to circumvent shortcomings such as reduced bioavailability, undesirable side effects, frequent dosing and unpleasant organoleptic properties of conventional drug delivery systems. The process of nanoencapsulation involves the use of biomaterials such as surfactants and/or polymers, often in combination with charge inducers and/or ligands for targeting. The biomaterials selected for nanoencapsulation processes must be as biocompatible as possible. The type(s) of biomaterials used for different nanoencapsulation approaches are highlighted and their use and applicability with regard to haemo- and, histocompatibility, cytotoxicity, genotoxicity and carcinogenesis are discussed.

27 May 2022 in Nanomaterials
Verified
Journal Article
Open access
PDF file
MLMiryam M. Luzala
Miryam M. Luzala
CMClaude Josué Muanga
Claude Josué Muanga
JKjoseph kyana
joseph kyana
JSJustin Bazibuhe Safari
Justin Bazibuhe Safari
EZEunice N. Zola
Eunice N. Zola
PMPatrick B. Memvanga
Patrick B. Memvanga
Metallic nanoparticles (MNPs) produced by green synthesis using plant extracts have attracted huge interest in the scientific community due to their excellent antibacterial, antifungal and antibiofilm activities. To evaluate these pharmacological properties, several methods or protocols have been successfully developed and implemented. Although these protocols were mostly inspired by the guidelines from national and international regulatory bodies, they suffer from a glaring absence of standardization of the experimental conditions. This situation leads to a lack of reproducibility and comparability of data from different study settings. To minimize these problems, guidelines for the antimicrobial and antibiofilm evaluation of MNPs should be developed by specialists in the field. Being aware of the immensity of the workload and the efforts required to achieve this, we set out to undertake a meticulous literature review of different experimental protocols and laboratory conditions used for the antimicrobial and antibiofilm evaluation of MNPs that could be used as a basis for future guidelines. This review also brings together all the discrepancies resulting from the different experimental designs and emphasizes their impact on the biological activities as well as their interpretation. Finally, the paper proposes a general overview that requires extensive experimental investigations to set the stage for the future development of effective antimicrobial MNPs using green synthesis.

1 June 2017 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
NCNkanga Christian
Nkanga Christian
RKRui Krause
Rui Krause
XNXavier Siwe Noundou
Xavier Siwe Noundou
RWRoderick Bryan Walker
Roderick Bryan Walker

30 November 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Aristote BuyaAristote Buya
Aristote Buya
Bwalya Angel WitikaBwalya Angel Witika
Bwalya Angel Witika
Alain BapolisiAlain Bapolisi
Alain Bapolisi
CMChiluba Mwila
Chiluba Mwila
GMGrady K. Mukubwa
Grady K. Mukubwa
NCNkanga Christian
Nkanga Christian
The antimicrobial drugs currently used for the management of tuberculosis (TB) exhibit poor bioavailability that necessitates prolonged treatment regimens and high dosing frequency to achieve optimal therapeutic outcomes. In addition, these agents cause severe adverse effects, as well as having detrimental interactions with other drugs used in the treatment of comorbid conditions such as HIV/AIDS. The challenges associated with the current TB regimens contribute to low levels of patient adherence and, consequently, the development of multidrug-resistant TB strains. This has led to the urgent need to develop newer drug delivery systems to improve the treatment of TB. Targeted drug delivery systems provide higher drug concentrations at the infection site, thus leading to reduced incidences of adverse effects. Lipid-based nanocarriers have proven to be effective in improving the solubility and bioavailability of antimicrobials whilst decreasing the incidence of adverse effects through targeted delivery. The potential application of lipid-based carriers such as liposomes, niosomes, solid lipid nanoparticles, nanostructured lipid carriers, nano and microemulsions, and self-emulsifying drug delivery systems for the treatment of TB is reviewed herein. The composition of the investigated lipid-based carriers, their characteristics, and their influence on bioavailability, toxicity, and sustained drug delivery are also discussed. Overall, lipid-based systems have shown great promise in anti-TB drug delivery applications. The summary of the reviewed data encourages future efforts to boost the translational development of lipid-based nanocarriers to improve TB therapy.

1 April 2021 in Virology
Verified
Journal Article
Closed access
NCNkanga Christian
Nkanga Christian
NSNicole Steinmetz
Nicole Steinmetz